Profile of romosozumab and its potential in the management of osteoporosis
Drug Design, Development and Therapy, 2017 Sian Yik Lim,1 Marcy B Bolster2 1Straub Bone & Joint Center, Straub Medical Center, Honolulu, HI, 2Division of Rheumatology, Allergy & Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA Abstract: Increased ...
Lim SY, Bolster MB
doaj +2 more sources
Meta-analysis of the effects of denosumab and romosozumab on bone mineral density and turnover markers in patients with osteoporosis [PDF]
Frontiers in Endocrinology, 2023 PurposeTo assess the alterations in bone mineral density and bone turnover marker concentrations following the administration of denosumab and romosozumab therapies in patients with osteoporosis.MethodsPubMed was searched for studies published until ...
Mingwei Hu +7 more
doaj +2 more sources
European Journal of Case Reports in Internal MedicineBackground: Romosozumab is a sclerostin-inhibiting monoclonal antibody that is effective and safe for anabolic treatment in patients with osteoporosis. Its main adverse effects are local; the severity of these injection-site reactions in clinical trials ...
Luis Antonio Rodriguez Arrieta +5 more
doaj +4 more sources
Comparative safety of denosumab and romosozumab in osteoporosis: an analysis based on the FDA adverse event reporting system database [PDF]
Frontiers in MedicineObjectiveDenosumab and romosozumab are two biological agents with potential immunomodulatory effects commonly used to treat osteoporosis. This study aimed to compare the safety of these two drugs using the FDA Adverse Event Reporting System (FAERS) with ...
Jian Sun +5 more
doaj +2 more sources
Romosozumab as Treatment for Severe Osteoporosis in Heart and Lung Transplant Recipients
EndocrinesBackground: Osteoporosis is common in transplant recipients, and fracture risk is high. Standard treatment is with anti-resorptive medications. Despite high fracture rates, there are limited data on the use of anabolic bone therapies in transplant ...
Lisa M. Raven +2 more
doaj +2 more sources
Romosozumab in Postmenopausal Korean Women with Osteoporosis: A Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study [PDF]
Endocrinology and Metabolism, 2021 Background This phase 3 study evaluated the efficacy and safety of 6-month treatment with romosozumab in Korean postmenopausal women with osteoporosis. Methods Sixty-seven postmenopausal women with osteoporosis (bone mineral density [BMD] T-scores ≤−2.5 ...
Ki-Hyun Baek +13 more
doaj +2 more sources
Romosozumab‐Associated Recurrent Erythema Nodosum in Mixed Connective Tissue Disease [PDF]
ACR Open RheumatologyObjective The aim of this study was to describe recurrent erythema nodosum (EN) temporally associated with romosozumab in a patient with mixed connective tissue disease and to examine the biologic plausibility of this association in the context of Wnt/β ...
Jose Luis Diaz Macip +5 more
doaj +2 more sources
The effect of romosozumab on bone mineral density depending on prior treatment: a prospective, multicentre cohort study in Switzerland [PDF]
Osteoporosis InternationalSUMMARY This multicentre, prospective cohort study measured the effect of romosozumab for 12 months on bone mineral density, taking into account prior therapies.
Judith Everts-Graber +1 more
exaly +2 more sources
Effectiveness of romosozumab following prior raloxifene treatment in primary osteoporosis: An observational study [PDF]
Bone ReportsRomosozumab is an anti-sclerostin antibody that increases bone formation and decreases bone resorption. It has been available for patients at high risk of osteoporotic fractures in Japan since 2019.
Kazuaki Mineta +4 more
doaj +2 more sources
JBMR PlusBackground: Optimization of sequential and combination treatment is crucial in shaping long-term management of postmenopausal osteoporosis (OP). Methods: We conducted a 6-month prospective observational study on postmenopausal women with severe OP ...
Pasetto, Emma +9 more
core +2 more sources